About Insulin-Glargine,Lixisenetide
Class: | Combination of long-acting insulin (Insulin Glargine) and GLP-1 receptor agonist (Lixisenatide)
Use: | Indicated for the treatment of type 2 diabetes mellitus in adults to improve glycemic control in conjunction with diet and exercise
Adult dose: | Initial dose is typically 15 units of Insulin Glargine and 5 mcg of Lixisenatide once daily, may be adjusted based on blood glucose levels; maximum dose is 60 units of Insulin Glargine and 20 mcg of Lixisenatide per day
Pediatric dose:
Drug Class
Combination of long-acting insulin (Insulin Glargine) and GLP-1 receptor agonist (Lixisenatide)
Uses & Indications
Indicated for the treatment of type 2 diabetes mellitus in adults to improve glycemic control in conjunction with diet and exercise
Storage Requirements
Store in the refrigerator (2°C to 8°C); can be kept at room temperature (up to 30°C) for up to 14 days after first use; do not freeze
Manufacturer & Packaging
Manufacturer: Sanofi-Aventis Groupe, FRANCE
Package Size
3ml Prefilled Pen x 3
Price & Supplier
Price in UAE: AED 606.00
Dosage Information
Adult Dose
Initial dose is typically 15 units of Insulin Glargine and 5 mcg of Lixisenatide once daily, may be adjusted based on blood glucose levels; maximum dose is 60 units of Insulin Glargine and 20 mcg of Lixisenatide per day
Pediatric Dose
Safety and efficacy have not been established in pediatric patients; not recommended for use in children
Side Effects
Common side effects include hypoglycemia, nausea, vomiting, diarrhea, headache, and injection site reactions
Contraindications & Precautions
Contraindicated in patients with a history of hypersensitivity to Insulin Glargine, Lixisenatide, or any component of the formulation; also contraindicated in patients with diabetic ketoacidosis
Important Warnings
Risk of serious hypoglycemia, especially when used with other antidiabetic medications; may cause pancreatitis; not recommended for use in patients with severe gastrointestinal disease or those with a history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice.
Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication.
The information presented here is specific to medicines available in UAE pharmacies and is regularly updated
to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.